Across TCGA pan-cancer cohorts, ALG3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ALG3 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ALG3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ALG3 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, LUAD, and COAD are the cancer types where ALG3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.305	0.833	.004	17	view →
LUAD	DFS	Median	II,III,IV	0.169	0.762	<.001	10	view →
COAD	DFS	Median	IV	0.432	0.916	.038	6	view →
PDAC	DFS	Quartile	III,IV	0.984	0.458	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ALG3 tumor-vs-normal RNA expression · all ALG3 data types